Anton Hansen
Chief Financial Officer
Replay available
Ascelia Pharma AB (publ) (ACE) Q2 2026 Earnings Call
Ascelia Pharma AB (publ) (STO: ACE) Q2 2026 earnings conference call, held 2026-08-20. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Magnus Corfitzen
Chief Executive Officer
Andreas Norlin
Chief Scientific Officer
George Tiglonov-Burek
Analyst, ABG Sundal Collier
Fredrik Thor
Analyst, Redeye
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.
Replay transcript excerpt
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a03fc1-85ff-7493-90b8-d9a230766a43 Created: 2026-08-26T20:27:24.184Z Duration: 1316.112 Channels: 1 00:00:00.000 -- 00:00:03.280 Welcome to Ascelia Pharma Q2 twenty twenty six 00:00:03.280 -- 00:00:04.560 Report Presentation. 00:00:04.799 -- 00:00:06.799 For the first part of the conference, participants 00:00:06.799 -- 00:00:08.719 will be in listen only mode. 00:00:08.800 -- 00:00:11.759 During the questions and answer session, participants are 00:00:11.759 -- 00:00:14.240 able to ask questions by dialing pound key 00:00:16.494 -- 00:00:18.255 Now I will hand the conference over to 00:00:18.255 -- 00:00:20.895 CEO, Magnus Korfetzen CFO, 00:00:20.895 -- 00:00:23.935 Anton Hansen and CSO, Andreas Norlin. 00:00:24.015 -- 00:00:24.735 Please go ahead. 00:00:26.650 -- 00:00:29.289 Thank you, and welcome everyone to the webcast 00:00:29.289 -- 00:00:32.250 for Ascelia Pharma's Q2 report for 2027. 00:00:33.850 -- 00:00:35.610 On this call, we will be making forward 00:00:35.610 -- 00:00:36.650 looking statements. 00:00:38.010 -- 00:00:39.850 On today's call, will start with an overview 00:00:39.850 -- 00:00:42.565 of Ascelia Pharma and recent key events, and 00:00:42.565 -- 00:00:44.965 then head into our portfolio update with an 00:00:44.965 -- 00:00:47.125 emphasis on the recent complete response letter for 00:00:47.125 -- 00:00:48.245 Orbiglans before 00:00:48.645 -- 00:00:51.125 moving to financials and priorities ahead. 00:00:51.765 -- 00:00:53.685 After the presentation, we will open up for 00:00:53.685 -- 00:00:54.005 questions. 00:00:55.890 -- 00:00:59.250 At Ascelia Pharma, we identify, develop, commercialize novel 00:00:59.250 -- 00:01:01.730 drugs that address unmet medical needs within rare 00:01:01....